Takuma Kato

Kagawa University
Country flagJapan

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (18)

Year:

2026

Year:

2026

Year:

2026

Objectives To investigate clinical outcomes, treatment, and survival rates of men aged ≥75 years with prostate cancer in Japan. Patients and Methods The study used data from the Prostate Cancer Research International: Active Surveillance (PRIAS)‐JAPAN, a nationwide, multicentre prospective cohort study of men with clinically localised prostate cancer managed with active surveillance (AS). The original eligibility criteria were clinical stage T1c–T2 disease, prostate‐specific antigen (PSA) level ≤10 ng/mL, PSA density (PSAD) <0.20 ng/mL/mL, and Gleason Score ≤3 + 3 with two or fewer positive biopsy cores. In 2021, magnetic resonance imaging use expanded eligibility to include patients with a PSA level ≤20 ng/mL, PSAD <0.25 ng/mL/mL, and Gleason Score ≤3 + 4 with <50% of biopsy cores positive. PSA was monitored every 3–6 months, and biopsies were scheduled at 1, 4, 7, and 10 years, and every 5 years thereafter. The outcomes in those aged ≥75 years (older group) were compared with those aged <75 years (younger group). Results Of the 1274 eligible patients enrolled by 29 February 2024, 231 were in the older group and 1043 were in the younger group. In the older group, the median age at enrolment was 77 years. At diagnosis, patients in the older group had significantly larger prostate volumes, higher proportion of Gleason Score 3 + 4, and more T2 disease than those in the younger group. The protocol biopsy acceptance rate decreased over time (first: 82.9%, second: 63.6%, third: 42.2%, fourth: 22.4%), with no significant difference between age groups. The 10‐year AS persistence rate in the older group was 8.8%. The overall survival was significantly lower in the older group than in the younger group (hazard ratio: 0.32, 95% confidence interval 0.14–0.74); however, the 10‐year metastasis‐free survival and cancer‐specific survival rates in the older group were both 100%. Conclusion In some patients aged ≥75 years an observation‐focused management approach may be appropriate, in which AS is initiated as a structured monitoring phase with planned de‐intensification and transition to watchful waiting, to prevent overtreatment while maintaining excellent cancer‐specific outcomes.

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Background Apalutamide treatment for prostate cancer may require discontinuation because of adverse events, particularly rashes. We evaluated the real-world outcomes of switching to other androgen receptor signaling inhibitors (ARSI) following such discontinuations. Methods This multicenter retrospective cohort study included men with metastatic castration-sensitive prostate cancer (mCSPC) and non-metastatic castration-resistant prostate cancer (nmCRPC) who received apalutamide between July 2019 and August 2025. Those who discontinued apalutamide comprised the switch group. We noted the reasons for discontinuation and compared progression-free survival (PFS) or metastasis-free survival (MFS) and overall survival (OS) between the switch and no-switch groups by disease category. Rash recurrence after switching was also assessed. Results Of 117 total patients, 17 (14.5%) comprised the switch group. Rashes accounted for all of the discontinuations, with 40% being grades ≥3. PFS and OS did not differ significantly between the switch and non-switch patients with mCSPC (log-rank P = .225 and P = .785, respectively), and similar MFS and OS results were observed in those with nmCRPC (P = .674 and P = .861, respectively). The rashes recurred after switching to alternative therapies in 5.8% (n = 1) of the patients. Conclusions This real-world multicenter analysis demonstrated that approximately one in seven patients with prostate cancer discontinued apalutamide treatment because they developed rashes. However, switching to other ARSIs preserved oncological outcomes, with no significant differences in PFS, MFS, or OS observed, regardless of prostate cancer subtype. Therefore, this type of switching does not appear to compromise subsequent treatment efficacy if it is done while the disease remains sensitive to ARSIs.

Year:

2026

Objectives Intermediate‐risk (IR) non‐muscle‐invasive bladder cancer (NMIBC) is a heterogeneous disease. In this study, we aimed to evaluate the efficacy of photodynamic diagnosis (PDD)‐assisted transurethral resection of the bladder (TURBT) using the recently validated International Bladder Cancer Group (IBCG) risk stratification model for IR‐NMIBC. Methods We conducted a single‐center retrospective analysis of 193 patients with IR‐NMIBC who underwent either PDD‐assisted with oral 5‐aminolevulinic acid ( n = 69) or white‐light (WL) TURBT ( n = 126) between 2009 and 2023. We performed 1:1 propensity score matching (PSM) to balance baseline characteristics. Recurrence‐free survival (RFS) was compared between the groups using the Kaplan–Meier method with subgroup analyses based on IBCG risk strata (IR‐low, IR‐intermediate/high). Results After PSM, 69 patients with well‐balanced characteristics remained in each group. PDD was associated with a significantly improved RFS compared with WL‐TURBT in the overall cohort ( p = 0.016). Using subgroup analysis, this benefit was most pronounced in the IR‐low risk group ( p = 0.025), whereas no significant difference was found in the IR‐intermediate/high‐risk group ( p = 0.14). Regarding multivariate analysis, PDD was an independent predictor of improved RFS in both the entire IR cohort (hazard ratio [HR]: 0.421, p = 0.009) and IR‐low subgroup (HR: 0.361, p = 0.047). Conclusions PDD‐assisted TURBT significantly improved the recurrence outcomes in patients with IR‐NMIBC, with the greatest benefit observed in the IR‐low risk subgroup. These findings support a stratified approach in which PDD is a cornerstone of management of IR‐low patients, while highlighting the need for further research to optimize treatment strategies for IR‐intermediate/high patients.

Year:

2026

Background/Objectives: The objective of this study was to evaluate the oncological outcomes and safety of nerve-sparing (NS) robot-assisted radical prostatectomy (RARP) when applied without Prostate Imaging-Reporting and Data System (PI-RADS) ≥3 lesions or Gleason pattern ≥4 on biopsy in the peripheral zone (PZ). Methods: We retrospectively analyzed 208 patients who underwent RARP between August 2017 and December 2022, excluding those who had received preoperative hormonal therapy. After NS status stratification and patient characteristic adjustment using propensity score matching (PSM), positive resection margin (RM) rates and prostate-specific antigen (PSA) recurrence-free survival were compared. Urinary and sexual quality of life (QOL) were assessed using the Expanded Prostate Cancer Index Composite, along with predictive factors associated with positive RM and RM locations in the NS group. Results: NS was performed in 68.6% (n = 129) patients. After PSM, there were no significant differences in RM positivity (p = 0.811) or PSA recurrence-free survival (Log-rank p = 0.79), regardless of NS status. There was no difference in sexual function between groups, but urinary QOL was significantly better in the NS group from the third month onward. In the NS group, RM positivity was 27.9% (n = 36), and diagnostic PSA (odds ratio [OR], 1.110, p = 0.038) and clinical T stage (OR, 1.400, p = 0.038) were predictive factors. The RM positivity rate on the NS side was 10.8%. Conclusions: NS, based on the absence of PI-RADS ≥3 lesions or Gleason pattern ≥4 in PZ, did not increase RM positivity rate and increased early urinary QOL.

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Collaborators (9)

Jun Miki

Associate Professor

-

JAPAN
View details

Yoshitaka Sekine

Gunma University

JAPAN
View details

Yuto Matsushita

Hamamatsu University School of Medicine

JAPAN
View details

Toyonori Tsuzuki

-

JAPAN
View details

Masatoshi Eto

-

JAPAN
View details

Masaki Shiota

Kyushu University

JAPAN
View details

Takahiro Kimura

Jikei University School of Medicine

JAPAN
View details

Mikio Sugimoto

Professor

Kagawa University

JAPAN
View details

Keita Kobayashi

Yamaguchi University

JAPAN
View details